title: Characterization of ovolin, an orally active tryptic peptide released from ovalbumin with anxiolytic-like activity.
abstract: We found that tryptic digest of ovalbumin after oral (p.o.) and intraperitoneal (i.p.) administration exhibited anxiolytic-like activity in mice, and then searched for orally active low-molecular-weight peptides with anxiolytic-like activity in the tryptic digest. Val-Tyr-Leu-Pro-Arg, named ovolin, corresponding to ovalbumin (280-284), mimicked the anxiolytic-like activity after p.o. and i.p. administration. The anxiolytic-like activity of ovolin was inhibited by indomethacin, a cyclooxygenase (COX) inhibitor, or BWA868C, an antagonist of the DP1 receptor for prostaglandin (PG) D2 . Ovolin-induced anxiolytic-like activity was also blocked by SCH58261 or bicuculline, antagonists of the adenosine A2A and GABAA receptors, respectively. Ovolin has no affinity for the DP1 , A2A and GABAA receptors. Taken together, ovolin may exhibit anxiolytic-like activity in a manner dependent on the PGD2 -DP1 system coupled to the A2A and GABAA receptors.
authors.affiliation: Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Gokasho Uji, Kyoto, Japan.
authors.forename: Ayako
authors.initials: A
authors.lastname: Oda
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kaneko
authors.forename: Takafumi
authors.initials: T
authors.lastname: Mizushige
authors.forename: Michael
authors.initials: M
authors.lastname: Lazarus
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Urade
authors.forename: Kousaku
authors.initials: K
authors.lastname: Ohinata
mesh_terms: D000284:Administration, Oral; D000818:Animals; D014151:Anti-Anxiety Agents; D001007:Anxiety / Q000523:psychology; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D007202:Indicators and Reagents; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010047:Ovalbumin / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D010455:Peptides / Q000737:chemistry; D015230:Prostaglandin D2 / Q000502:physiology; D011492:Protein Hydrolysates / Q000737:chemistry; D043705:Receptor, Adenosine A2A / Q000187:drug effects / Q000502:physiology; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors / Q000187:drug effects; D013329:Structure-Activity Relationship; D014357:Trypsin / Q000737:chemistry*
chemical_list: D014151:Anti-Anxiety Agents; D007202:Indicators and Reagents; D010446:Peptide Fragments; D010455:Peptides; D011492:Protein Hydrolysates; D043705:Receptor, Adenosine A2A; D011963:Receptors, GABA-A; D011982:Receptors, Prostaglandin; C582786:valyl-tyrosyl-leucyl-prolyl-arginine; D010047:Ovalbumin; D014357:Trypsin; D015230:Prostaglandin D2